Market Overview

Insmed Shares Rise 100% After Positive Results From Lung Disease Study


Insmed Incorporated (NASDAQ: INSM) shares are trading higher by $13.80, or 112 percent, at $26.09 in Tuesday's session.

The catalyst for the rally is the announcement of positive top-line results from its Phase 3 Convert study of ALIS in adult patients with treatment-refractory nontuberculous Mycobacterial (NTM) lung disease.

Its much higher opening print of $29.50 is only two cents from the high for the day ($29.52), which exceeds its former all-time high from March 2006 at $27.90.

Since reaching that elevated level, profit-takers have come into Insmed and it has drifted lower. As of 11:15 a.m. EST, the stock has fallen to $25.38 and is trying to remain in the $26.00 handle.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (INSM)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Study: Ending DACA Would Cost Nearly $500 Billion Loss Of GDP; 10 States That Would Bear The Biggest Brunt

Why It's Useful To Know A Company's Competitors When Trading